Shares of Carl Zeiss Meditec AG (OTCMKTS:CZMWY – Get Free Report) gapped down prior to trading on Wednesday after Barclays downgraded the stock from a hold rating to a strong sell rating. The stock had previously closed at $38.10, but opened at $35.47. Carl Zeiss Meditec shares last traded at $35.48, with a volume of 4,922 shares trading hands.
A number of other research firms also recently issued reports on CZMWY. The Goldman Sachs Group downgraded shares of Carl Zeiss Meditec from a “hold” rating to a “sell” rating in a research note on Monday, October 5th. UBS Group downgraded shares of Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a research note on Tuesday, August 11th. Morgan Stanley began coverage on Carl Zeiss Meditec in a report on Wednesday, September 2nd. They set an “underweight” rating for the company. Finally, Zacks Research raised Carl Zeiss Meditec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 6th. Two analysts have rated the stock with a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Strong Sell”.
Get Our Latest Stock Report on Carl Zeiss Meditec
Carl Zeiss Meditec Price Performance
The firm has a 50-day simple moving average of $36.75 and a two-hundred day simple moving average of $33.01.
About Carl Zeiss Meditec
Carl Zeiss Meditec AG is a medical technology company headquartered in Jena, Germany, and part of the ZEISS Group. The company develops, manufactures and distributes equipment and solutions for ophthalmology and microsurgery, serving hospitals, clinics and medical professionals worldwide. Its ophthalmic portfolio includes diagnostic systems for examining the eye, equipment for cataract and refractive surgery, surgical lasers, intraocular lenses and other related products. The company also supplies surgical microscopes, visualization systems and digital technologies used in neurosurgery, spine surgery, ear, nose and throat procedures, and other microsurgical specialties.
Featured Stories
- Five stocks we like better than Carl Zeiss Meditec
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.
